ABUS (Arbutus Biopharma) Risk Assessment


ABUS Arbutus Biopharma Corp ABUS
53 GF Score
Price $5.01
GF Value $51.09
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Arbutus Biopharma is: High Risk: High uncertainty.

Arbutus Biopharma  (NAS:ABUS) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Arbutus Biopharma Risk Assessment Related Terms

ABUS vs EVMN, ANNX, TBPH: Risk Assessment Comparison

For the Biotechnology subindustry, Arbutus Biopharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arbutus Biopharma Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Risk Assessment falls into.


ABUS
53GF Score
Arbutus Biopharma Corp ABUS
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $5.01 is trading 90.2% below its estimated GF Value™ of $51.09. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

  • Risk Assessment:
  • GF Value™: $51.09 vs. price of $5.01 (90.2% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges I9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score

Get the complete analysis for ABUS

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.01
Price
$51.09
GF Value